PRA Health Sciences, a leading global contract research organization, today announced its new Predictivv™ platform, the beginning of an entirely new approach on the role technology will play in the future of clinical development. The Predictivv™ platform will be a fully integrated solution for designing, planning and optimizing the management of global clinical studies. Designed around a unified platform that harmonizes data, processes, and people across every aspect of a clinical study, Predictivv™ will enable unprecedented adaptive intelligence and decision support for the ever-increasing complexities of the clinical development process.
“Predictivv™ is another step in PRA’s ambitious goal to change the future of clinical development,” said CEO Colin Shannon. “As we enter a new era of clinical development led by ideas like adaptive trial design and riskâbased monitoring, we recognized that existing clinical-trial management solutions did not support the realâtime modifications of protocols and operational plans required by adaptive models and the high risks associated with managing this complexity.”
The Predictivv™ platform will seamlessly bring together a series of clinical study applications representing the foundation of a true end-to-end clinical development process. Predictivv™ combines data input and continuous feedback from across the spectrum of the trial process, empowering decision support intelligence throughout the entire clinical lifecycle.
“One of the primary goals we established when designing the Predictivv platform was to provide the industry with unprecedented transparency into their portfolio of studies,” said Shannon. Through a proprietary analytics engine, Predictivv™ will not only provide transparency into all key processes and their statuses, but it will be capable of proactively identifying process and protocol deviations, enabling course corrections before risks occur.
Among the first applications that will be available in the PredictivvTM platform is Predictivv Connect™. Connect is a highly configurable solution that provides real time insights into every phase of clinical trial management, empowering clients and key stakeholders to connect and use data within their studies in an entirely new way.
With its investment in the Predictivv™ platform, PRA anticipates launching several new applications that focus on key aspects of clinical trial management, including areas such as site selection, patient recruitment and investigator engagement. PredictivvTM applications will be device independent, allowing users to explore data, uncover new insights and take action instantly from any device.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.